Latest Pdl Biopharma (PDLI) Headlines Morning M
Post# of 35
Posted On: 03/13/2014 12:26:04 PM
Latest Pdl Biopharma (PDLI) Headlines
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
PDL BioPharma Completes Regular Quarterly Dividend Payment
PR Newswire - Wed Mar 12, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2014, the record date.
PDL BioPharma Expects Higher Q1 Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:10AM CDT
PDL BioPharma announced that it expects to receive revenues of roughly $133 million in the first quarter of 2014.
PDL BioPharma Provides First Quarter 2014 Revenue Guidance of $133 Million
PR Newswire - Tue Mar 11, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase.
PDL BioPharma Appoints David Gryska to its Board of Directors
PR Newswire - Mon Mar 10, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the appointment of David W. Gryska to its board of directors. Mr. Gryska brings more than 30 years of strategic biopharmaceutical and financial leadership experience to PDL and has demonstrated success in implementing successful strategic initiatives, growing companies and executing multi-billion dollar financial transactions.
Buy-Rated Dividend Stocks In The Top 3: PDLI, RCI, CVI
at The Street - Fri Mar 07, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
PDL BioPharma Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:20AM CST
PDL BioPharma posted fourth-quarter 2013 earnings of 39 cents per share, below the Zacks Consensus Estimate of 41 cents.
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PR Newswire - Tue Mar 04, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:
PDL BioPharma's Q4 Profit Jumps 24% on Higher Royalty Revenue
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 5:04PM CST
The biopharmaceutical sector's most lucrative dividend-paying company, PDL BioPharma , reported its fourth-quarter earnings results after the bell this evening. Based on early indications, it would appear that everything seems to be headed in the...
PDL BioPharma Announces Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 03, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2013.
Buy-Rated Dividend Stocks: Top 3 Companies: POM, PDLI, KKR
at The Street - Wed Feb 26, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
PDL BioPharma to Announce Fourth Quarter and Full Year 2013 Financial Results on March 3, 2014
PR Newswire - Mon Feb 24, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2013 financial results for the period ended December 31, 2013, on Monday, March 3, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDL BioPharma to Present at Upcoming Investor Conferences
PR Newswire - Wed Feb 19, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences.
PDL BioPharma and Paradigm Spine Complete a $75 Million Financing Transaction
PR Newswire - Tue Feb 18, 6:00AM CST
PDL BioPharma, Inc. (NASDAQ: PDLI) and Paradigm Spine, LLC, a provider of innovative spinal implant technologies, announced today that the parties have entered into a credit agreement whereby PDL will provide Paradigm with up to $75 million of secured debt financing. Armentum Partners acted as financial advisors to Paradigm Spine for the transaction.
2 Health Care Partnerships Go Head-To-Head
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
The health care space is full of collaborative arrangements, with many pharmaceutical companies in particular forming partnerships with peers to share the development costs (and risk) involved in developing new drugs and treatments. However,...
PDL BioPharma Inc retains Dr Stephen Hoffman as senior advisor for biotech & pharma
M2 - Fri Feb 14, 3:01AM CST
Antibody humanization company PDL BioPharma Inc (NasdaqGS
DLI) reported on Thursday the reelection of Stephen J Hoffman, MD PhD as its senior advisor with effect from 3 February 2014.
PDL BioPharma Retains Dr. Stephen Hoffman as Senior Advisor
PR Newswire - Thu Feb 13, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has retained Stephen J. Hoffman, M.D., Ph.D. as senior advisor to the Company, effective as of February 3, 2014. PDL is focused on acquiring income generating assets to continue increasing shareholder value. Dr. Hoffman brings more than 25 years of experience in biotech and pharma investing and leadership.
PDL BioPharma Inc announces USD300m convertible senior notes due 2018
M2 - Thu Feb 13, 3:40AM CST
Antibody company PDL BioPharma Inc (NasdaqGSDL) reported on Wednesday the completion of its offering of USD300m convertible senior unsecured notes maturing on 1 February 2018.
PDL BioPharma Issues $300 Million of Convertible Senior Notes due 2018
PR Newswire - Wed Feb 12, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes maturing on February 1, 2018 (2018 Notes). PDL issued $300 million aggregate principal amount of 2018 Notes, which included $39.13 million aggregate principal amount of 2018 Notes issued pursuant to the exercise of the underwriters' overallotment option to purchase additional 2018 Notes. In connection with the offering of the 2018 Notes, PDL entered into privately negotiated convertible note hedge transactions with affiliates of RBC Capital Markets and Wells Fargo Securities ("hedge counterparties") and privately negotiated warrant transactions with the hedge counterparties relating to the same number of shares of PDL's common stock. RBC Capital Markets and Wells Fargo Securities acted as joint book-running managers for the 2018 Notes offering. Cowen and Company and Janney Montgomery Scott acted as co-managers.
Buy-Rated Dividend Stocks In The Top 5: ED, APU, GLNG, PDLI, NNN
at The Street - Tue Feb 11, 9:30AM CST
These 5 dividend stocks are rated a Buy by TheStreet
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
PDL BioPharma Completes Regular Quarterly Dividend Payment
PR Newswire - Wed Mar 12, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2014, the record date.
PDL BioPharma Expects Higher Q1 Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:10AM CDT
PDL BioPharma announced that it expects to receive revenues of roughly $133 million in the first quarter of 2014.
PDL BioPharma Provides First Quarter 2014 Revenue Guidance of $133 Million
PR Newswire - Tue Mar 11, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase.
PDL BioPharma Appoints David Gryska to its Board of Directors
PR Newswire - Mon Mar 10, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the appointment of David W. Gryska to its board of directors. Mr. Gryska brings more than 30 years of strategic biopharmaceutical and financial leadership experience to PDL and has demonstrated success in implementing successful strategic initiatives, growing companies and executing multi-billion dollar financial transactions.
Buy-Rated Dividend Stocks In The Top 3: PDLI, RCI, CVI
at The Street - Fri Mar 07, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
PDL BioPharma Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:20AM CST
PDL BioPharma posted fourth-quarter 2013 earnings of 39 cents per share, below the Zacks Consensus Estimate of 41 cents.
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PR Newswire - Tue Mar 04, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:
PDL BioPharma's Q4 Profit Jumps 24% on Higher Royalty Revenue
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 5:04PM CST
The biopharmaceutical sector's most lucrative dividend-paying company, PDL BioPharma , reported its fourth-quarter earnings results after the bell this evening. Based on early indications, it would appear that everything seems to be headed in the...
PDL BioPharma Announces Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 03, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2013.
Buy-Rated Dividend Stocks: Top 3 Companies: POM, PDLI, KKR
at The Street - Wed Feb 26, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
PDL BioPharma to Announce Fourth Quarter and Full Year 2013 Financial Results on March 3, 2014
PR Newswire - Mon Feb 24, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2013 financial results for the period ended December 31, 2013, on Monday, March 3, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDL BioPharma to Present at Upcoming Investor Conferences
PR Newswire - Wed Feb 19, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences.
PDL BioPharma and Paradigm Spine Complete a $75 Million Financing Transaction
PR Newswire - Tue Feb 18, 6:00AM CST
PDL BioPharma, Inc. (NASDAQ: PDLI) and Paradigm Spine, LLC, a provider of innovative spinal implant technologies, announced today that the parties have entered into a credit agreement whereby PDL will provide Paradigm with up to $75 million of secured debt financing. Armentum Partners acted as financial advisors to Paradigm Spine for the transaction.
2 Health Care Partnerships Go Head-To-Head
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
The health care space is full of collaborative arrangements, with many pharmaceutical companies in particular forming partnerships with peers to share the development costs (and risk) involved in developing new drugs and treatments. However,...
PDL BioPharma Inc retains Dr Stephen Hoffman as senior advisor for biotech & pharma
M2 - Fri Feb 14, 3:01AM CST
Antibody humanization company PDL BioPharma Inc (NasdaqGS
DLI) reported on Thursday the reelection of Stephen J Hoffman, MD PhD as its senior advisor with effect from 3 February 2014. PDL BioPharma Retains Dr. Stephen Hoffman as Senior Advisor
PR Newswire - Thu Feb 13, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has retained Stephen J. Hoffman, M.D., Ph.D. as senior advisor to the Company, effective as of February 3, 2014. PDL is focused on acquiring income generating assets to continue increasing shareholder value. Dr. Hoffman brings more than 25 years of experience in biotech and pharma investing and leadership.
PDL BioPharma Inc announces USD300m convertible senior notes due 2018
M2 - Thu Feb 13, 3:40AM CST
Antibody company PDL BioPharma Inc (NasdaqGS
DL) reported on Wednesday the completion of its offering of USD300m convertible senior unsecured notes maturing on 1 February 2018. PDL BioPharma Issues $300 Million of Convertible Senior Notes due 2018
PR Newswire - Wed Feb 12, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes maturing on February 1, 2018 (2018 Notes). PDL issued $300 million aggregate principal amount of 2018 Notes, which included $39.13 million aggregate principal amount of 2018 Notes issued pursuant to the exercise of the underwriters' overallotment option to purchase additional 2018 Notes. In connection with the offering of the 2018 Notes, PDL entered into privately negotiated convertible note hedge transactions with affiliates of RBC Capital Markets and Wells Fargo Securities ("hedge counterparties") and privately negotiated warrant transactions with the hedge counterparties relating to the same number of shares of PDL's common stock. RBC Capital Markets and Wells Fargo Securities acted as joint book-running managers for the 2018 Notes offering. Cowen and Company and Janney Montgomery Scott acted as co-managers.
Buy-Rated Dividend Stocks In The Top 5: ED, APU, GLNG, PDLI, NNN
at The Street - Tue Feb 11, 9:30AM CST
These 5 dividend stocks are rated a Buy by TheStreet
(0)
(0)PDL BioPharma Inc. (PDLI) Stock Research Links
Scroll down for more posts ▼